Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016

Int J Infect Dis. 2021 Jan:102:337-343. doi: 10.1016/j.ijid.2020.10.078. Epub 2020 Oct 29.

Abstract

Introduction: This study assessed the seroprevalence against all three polioviruses among the last cohort of infants aged 6-11 months who received tOPV before the tOPV-bOPV switch and had an opportunity to receive a full dose of inactivated poliovirus vaccine introduced in the routine immunization schedule.

Methods: Serum was tested for neutralizing antibodies against polioviruses among infants residing in three different risk- category states for poliovirus transmission in India viz., Bihar historically high-risk state for polio, Madhya Pradesh a State with low routine immunization coverage and Chhattisgarh with lower acute flaccid paralysis surveillance indicators.

Results: A total of 1113 serum samples were tested across the three states. The overall seroprevalence was 98.5% (97.7-99.2), 98.9% (98.3-99.5) and 94.4% (93.0-95.8) for poliovirus types 1, 2 and 3 respectively. The median antibody titers for corresponding serotypes were 575, 362 and 181. Infants who received five doses of tOPV showed respective seroprevalence rates of 98.7%, 98.7% and 93.7% against types 1, 2 and 3 polioviruses. There was no significant difference in seroprevalence across the group of IPV recipients. The median reciprocal titers across the groups of IPV recipient was significantly higher (p = 0.006) for poliovirus-3.

Conclusion: The seroprevalence rates observed in the study are historically the highest in the series of serosurveys that India has conducted to assess the population immunity against polioviruses. Poliovirus 2 seroprevalence was very high at the time of the tOPV-bOPV switch in India effected in April 2016.

Keywords: 2016; India; Polio; Seroprevalence; Switch; bOPV; tOPV.

MeSH terms

  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Cross-Sectional Studies
  • Female
  • Humans
  • India / epidemiology
  • Infant
  • Male
  • Poliomyelitis / epidemiology*
  • Poliomyelitis / immunology
  • Poliomyelitis / prevention & control
  • Poliomyelitis / virology
  • Poliovirus / classification
  • Poliovirus / isolation & purification
  • Poliovirus Vaccine, Inactivated / administration & dosage
  • Poliovirus Vaccine, Oral / administration & dosage*
  • Seroepidemiologic Studies
  • Serogroup

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Poliovirus Vaccine, Inactivated
  • Poliovirus Vaccine, Oral